Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -191.12% | -243.56% | -226.90% | 62.96% | 55.45% |
| Total Depreciation and Amortization | -93.47% | -54.13% | -54.22% | -51.82% | 61.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.60% | -36.04% | -44.96% | -50.84% | -36.33% |
| Change in Net Operating Assets | 105.84% | 104.14% | 91.65% | -1,076.91% | -1,106.52% |
| Cash from Operations | 2.88% | -9.23% | -29.56% | -78.39% | -46.29% |
| Capital Expenditure | -22.98% | 16.06% | 42.47% | 25.79% | 27.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -127.78% | -372.14% | -881.99% | 0.79% | 312.25% |
| Cash from Investing | -135.60% | -485.85% | -391.09% | 4.35% | 276.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,801.92% | 65.51% | 63.03% | 66.18% | -94.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,617.76% | 57.68% | 63.03% | 66.18% | -94.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.67% | -294.68% | -148.67% | 79.68% | -20.46% |
